Replicor Inc. is a Canadian biotechnology company focused on the development of its nucleic acid polymer (NAP) technology for the treatment of hepatitis B (HBV) and delta (HDV) infections.

NAPs are the only antiviral agent to directly target the immunosuppressive protein (HBsAg) which drives chronic HBV infection and liver disease.  Our lead clinical NAP drug product is REP 2139-Mg, a proprietary formulation of REP 2139 which makes once weekly subcutaneous injections easily tolerated.

Replicor's latest clinical data demonstrates that NAP-based combination therapy can restore immune control of HBV infection in 78% of patients and eliminate HDV infection in 74% of patients.  These effects persist in the absence of any therapy, allowing the liver to heal.

REP 2139-Mg based combination promises to revolutionize the therapy of chronic HBV and HDV infection and play a pivotal role in the WHO's goal of eliminating viral hepatitis by 2030.

Replicor Inc.

Org chart

Teams

Offices